Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Income (2023 - 2025)

Historic Non Operating Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to $4.5 million.

  • Day One Biopharmaceuticals' Non Operating Income fell 3058.75% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 8408.85%. This contributed to the annual value of $128.9 million for FY2024, which is 65184.0% up from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Non Operating Income stood at $4.5 million for Q3 2025, which was down 3058.75% from $4.7 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Non Operating Income's 5-year high stood at $112.0 million during Q2 2024, with a 5-year trough of $3.4 million in Q2 2023.
  • In the last 3 years, Day One Biopharmaceuticals' Non Operating Income had a median value of $5.0 million in 2023 and averaged $15.7 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Non Operating Income skyrocketed by 320144.5% in 2024 and then crashed by 9584.46% in 2025.
  • Quarter analysis of 3 years shows Day One Biopharmaceuticals' Non Operating Income stood at $5.0 million in 2023, then increased by 21.69% to $6.1 million in 2024, then decreased by 25.72% to $4.5 million in 2025.
  • Its Non Operating Income was $4.5 million in Q3 2025, compared to $4.7 million in Q2 2025 and $5.1 million in Q1 2025.